Similar to ANXA2, the high expression rate of HE4 in stage III–IV endometrial carcinoma was 66.7 % (16/24), which was significantly higher than stage I–II (36.7 % [22/60]; p < 0.05) (Table 2). The gene discussed is ANXA2; the disease is endometrial carcinoma.